Systemic reactions to ophthalmic drug preparations

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Adverse systemic reactions associated with the use of topical ophthalmic timolol, chloramphenicol, phenylephrine and cyclopentolate are surveyed, with special emphasis on precautions and contraindications for these ophthalmic drug preparations. Systemic reactions secondary to timolol, a β-adrenergic antagonist indicate that it should be used with caution in patients with asthma or a history of asthma, chronic obstructive pulmonary disease or cardiovascular disease and in those patients receiving systemic administration of β-blockers or verapamil. Because significant blood dyscrasias or aplastic anaemia have been reported following topical ophthalmic chloramphenicol, the only absolute indication in ocular conditions is an organism that is resistant to all other antibiotics. Both 2.5% and 10% phenylephrine have been associated with cardiovascular effects and should be used with caution in selected patients on monoamine oxidase inhibitors, tricyclic antidepressants or atropine or in those with hypertension, advanced arteriosclerotic changes, aneurysms, orthostatic hypotension, long-standing insulin-dependent diabetes and in children with low bodyweights. Central nervous system toxicity secondary to cyclopentolate is dose-related and can be avoided by use of minimal concentrations and avoidance of unnecessary repetition of administration. Occlusion of the nasolacrimal passage with finger pressure immediately after instillation of any eyedrop also decreases the amount of drug that is absorbed systemically.

Original languageEnglish (US)
Pages (from-to)287-293
Number of pages7
JournalMedical Toxicology and Adverse Drug Experience
Volume2
Issue number4
StatePublished - 1987

Fingerprint

Cyclopentolate
Timolol
Drug Compounding
Phenylephrine
Chloramphenicol
Pulmonary diseases
Adrenergic Antagonists
Monoamine Oxidase Inhibitors
Ophthalmic Solutions
Tricyclic Antidepressive Agents
Neurology
Medical problems
Verapamil
Atropine
Pharmaceutical Preparations
Toxicity
Blood
Asthma
Insulin
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Toxicology

Cite this

Systemic reactions to ophthalmic drug preparations. / Fraunfelder, Frederick (Fritz); Meyer, S. M.

In: Medical Toxicology and Adverse Drug Experience, Vol. 2, No. 4, 1987, p. 287-293.

Research output: Contribution to journalArticle

@article{e6ac77722c5a443183f6f82ab3a7d272,
title = "Systemic reactions to ophthalmic drug preparations",
abstract = "Adverse systemic reactions associated with the use of topical ophthalmic timolol, chloramphenicol, phenylephrine and cyclopentolate are surveyed, with special emphasis on precautions and contraindications for these ophthalmic drug preparations. Systemic reactions secondary to timolol, a β-adrenergic antagonist indicate that it should be used with caution in patients with asthma or a history of asthma, chronic obstructive pulmonary disease or cardiovascular disease and in those patients receiving systemic administration of β-blockers or verapamil. Because significant blood dyscrasias or aplastic anaemia have been reported following topical ophthalmic chloramphenicol, the only absolute indication in ocular conditions is an organism that is resistant to all other antibiotics. Both 2.5{\%} and 10{\%} phenylephrine have been associated with cardiovascular effects and should be used with caution in selected patients on monoamine oxidase inhibitors, tricyclic antidepressants or atropine or in those with hypertension, advanced arteriosclerotic changes, aneurysms, orthostatic hypotension, long-standing insulin-dependent diabetes and in children with low bodyweights. Central nervous system toxicity secondary to cyclopentolate is dose-related and can be avoided by use of minimal concentrations and avoidance of unnecessary repetition of administration. Occlusion of the nasolacrimal passage with finger pressure immediately after instillation of any eyedrop also decreases the amount of drug that is absorbed systemically.",
author = "Fraunfelder, {Frederick (Fritz)} and Meyer, {S. M.}",
year = "1987",
language = "English (US)",
volume = "2",
pages = "287--293",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Systemic reactions to ophthalmic drug preparations

AU - Fraunfelder, Frederick (Fritz)

AU - Meyer, S. M.

PY - 1987

Y1 - 1987

N2 - Adverse systemic reactions associated with the use of topical ophthalmic timolol, chloramphenicol, phenylephrine and cyclopentolate are surveyed, with special emphasis on precautions and contraindications for these ophthalmic drug preparations. Systemic reactions secondary to timolol, a β-adrenergic antagonist indicate that it should be used with caution in patients with asthma or a history of asthma, chronic obstructive pulmonary disease or cardiovascular disease and in those patients receiving systemic administration of β-blockers or verapamil. Because significant blood dyscrasias or aplastic anaemia have been reported following topical ophthalmic chloramphenicol, the only absolute indication in ocular conditions is an organism that is resistant to all other antibiotics. Both 2.5% and 10% phenylephrine have been associated with cardiovascular effects and should be used with caution in selected patients on monoamine oxidase inhibitors, tricyclic antidepressants or atropine or in those with hypertension, advanced arteriosclerotic changes, aneurysms, orthostatic hypotension, long-standing insulin-dependent diabetes and in children with low bodyweights. Central nervous system toxicity secondary to cyclopentolate is dose-related and can be avoided by use of minimal concentrations and avoidance of unnecessary repetition of administration. Occlusion of the nasolacrimal passage with finger pressure immediately after instillation of any eyedrop also decreases the amount of drug that is absorbed systemically.

AB - Adverse systemic reactions associated with the use of topical ophthalmic timolol, chloramphenicol, phenylephrine and cyclopentolate are surveyed, with special emphasis on precautions and contraindications for these ophthalmic drug preparations. Systemic reactions secondary to timolol, a β-adrenergic antagonist indicate that it should be used with caution in patients with asthma or a history of asthma, chronic obstructive pulmonary disease or cardiovascular disease and in those patients receiving systemic administration of β-blockers or verapamil. Because significant blood dyscrasias or aplastic anaemia have been reported following topical ophthalmic chloramphenicol, the only absolute indication in ocular conditions is an organism that is resistant to all other antibiotics. Both 2.5% and 10% phenylephrine have been associated with cardiovascular effects and should be used with caution in selected patients on monoamine oxidase inhibitors, tricyclic antidepressants or atropine or in those with hypertension, advanced arteriosclerotic changes, aneurysms, orthostatic hypotension, long-standing insulin-dependent diabetes and in children with low bodyweights. Central nervous system toxicity secondary to cyclopentolate is dose-related and can be avoided by use of minimal concentrations and avoidance of unnecessary repetition of administration. Occlusion of the nasolacrimal passage with finger pressure immediately after instillation of any eyedrop also decreases the amount of drug that is absorbed systemically.

UR - http://www.scopus.com/inward/record.url?scp=0023200578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023200578&partnerID=8YFLogxK

M3 - Article

C2 - 3306268

AN - SCOPUS:0023200578

VL - 2

SP - 287

EP - 293

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 4

ER -